~~<i id='C2D30509B9'><strike id='C2D30509B9'><tt id='C2D30509B9'><pre id='C2D30509B9'></pre></tt></strike></i>~~

Home» explore» knowledge

knowledge

author：entertainment 2025-09-28 11:42:04 Page View：3

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Moderna says combo Covid
Next article： As demand for Covid shots wanes, Moderna seeks its next success

explore

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

FILE-Abortion-rightsprotestersfillIndianaStatehousecorridorsandcheeroutsidelegislativechambers,Frida

Lilly's Alzheimer's drug donanemab backed by FDA advisers

DarronCummings/APAdviserstotheFoodandDrugAdministrationvoted11-0onMondaytorecommendtheapprovalofadru

How one medical school became remarkably diverse

ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri

Report captures long Covid’s disabling effects and policy challenges

RidinganearlyemptyStatenIslandferryearlyinthepandemicin2020.SpencerPlatt/GettyImagesTheCovidpandemic